Intervention not reported
RT40 (4 RCTs; 930 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT40); radiotherapy with 60 Gy in…
The intervention may leads to lower RT40 (4 RCTs; 930 participants) (low certainty).
1 finding from 1 review
Intervention not reported
TMZ (3 RCTs, 538 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT40); radiotherapy with 60 Gy in…
The intervention may leads to lower TMZ (3 RCTs, 538 participants) (low certainty).
1 finding from 1 review
Intervention not reported
CRT (2 RCTs; 635 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT40); radiotherapy with 60 Gy in…
The intervention led to lower CRT (2 RCTs; 635 participants); GRADE not reported.
1 finding from 1 review
Intervention not reported
BEV_CRT (1 RCT; 73 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT40); radiotherapy with 60 Gy in…
The intervention led to lower BEV_CRT (1 RCT; 73 participants); GRADE not reported.
1 finding from 1 review
Intervention not reported
RT 40 (4 RCTs; 930 participants) · elderly people with newly diagnosed glioblastoma Interventions: chemoradiotherapy (CRT); chemoradiotherapy plus bevacizumab (BEV_CRT);…
1 finding from 1 review
Intervention not reported
BEV_RT (1 RCT; 75 participants) · elderly people with newly diagnosed glioblastoma Interventions: chemoradiotherapy (CRT); chemoradiotherapy plus bevacizumab (BEV_CRT);…
The intervention showed no clear difference in BEV_RT (1 RCT; 75 participants) (low certainty).
1 finding from 1 review
Intervention not reported
PFS (stage III/IV) Median · women with advanced (stage III/IV) endometrial cancer after surgery and radiotherapy
The intervention showed no clear difference in PFS (stage III/IV) Median (moderate certainty).
1 finding from 1 review
Progression‐free survival · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with maintenance radiotherapy (low certainty).
3 findings from 1 review
RR 1.07 [0.75, 1.54]
1 study · 141 participants
Low
RR 0.86 [0.55, 1.37]
1 study · 141 participants
Low
RR 0.89 [0.51, 1.55]
1 study · 141 participants
Low
3‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review
5‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 5‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review
10‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 10‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review
Overall survival: higher‐dose WBRT vs control (3000 cGy/10 daily fractions)No. of participants: 846(4 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules probably leads to higher overall survival: lower‐dose WBRT vs control WBRT (3000 cGy/10 daily… compared with WBRT control (moderate certainty).
2 findings from 1 review
HR 1.21 [1.04, 1.4]
Studies not reported
Moderate
HR 0.97 [0.83, 1.12]
Studies not reported
Moderate
Brain tumour response rates: complete response (CR) and partial response (PR) combinedNo. of participants: 847(6 RCTs) · patients with newly diagnosed multiple brain metastases
WBRT with radiosensitisers (radiosen) showed no clear difference in brain tumour response rates: complete response (CR) and partial… compared with WBRT alone (high certainty).
1 finding from 1 review
OR 0.84 [0.63, 1.11]
Studies not reported
High
Adverse effectsNo. of participants: 1754(9 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
High
Quality of lifeNo. of participants: 271(2 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Symptom controlNo. of participants: 1814(3 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Overall survivalNo. of participants: 2631(8 RCTs) · patients with newly diagnosed multiple brain metastases
WBRT and radiosurgery showed no clear difference in overall survivalNo. of participants: 358(2 RCTs) compared with WBRT (moderate certainty).
1 finding from 1 review
HR 0.61 [0.27, 1.39]
Studies not reported
Moderate
1‐Year overall brain control ratesNo. of participants: 400(3 RCTs) · patients with newly diagnosed multiple brain metastases
WBRT and radiosurgery leads to lower 1‐Year overall brain control ratesNo. of participants: 400(3 RCTs) compared with WBRT (high certainty).
1 finding from 1 review
HR 0.39 [0.25, 0.6]
Studies not reported
High
Adverse effectsNo. of participants: 1754(9 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
High
Intracranial progression‐free durationNo. of participants: 400(3 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
High